Market Research Logo

Serbia Pharmaceuticals and Healthcare Report Q4 2017

BMI View:

Serbia will remain an unattractive market for multinational drugmakers in comparison to itsregional neighbours. The poor healthcare system will continue to limit opportunities while economic issueswill dampen the outlook for both pharmaceutical sales and healthcare expenditure.

Headline Expenditure ProjectionsPharmaceuticals: RSD92.1bn (USD822mn) in 2016 to RSD94.2bn (USD845mn) in 2017; 2.3% in localcurrency terms and 2.8% in US dollar terms. Forecast unchanged from previous quarter.

Healthcare: RSD423.4bn (USD3.78bn) in 2016 to RSD440.5bn (USD3.95bn) in 2017; 4.0% in localcurrency terms and 4.5% in US dollar terms. Forecast unchanged from previous quarter.


BMI Industry View
Table: Headline Pharmaceuticals & Healthcare Forecasts (Serbia 2015-2021)
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Serbia 2013-2021)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2013-2021)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2013-2021)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2013-2021)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Serbia 2013-2021)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Serbia 2013-2021)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Serbia 2013-2021)
OTC Medicine Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Serbia 2013-2021)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Serbia 2015-2021)
Table: Pharmaceutical Trade Data And Forecasts local currency (Serbia 2015-2021)
Industry Risk/Reward Index
Central And Eastern Europe Pharmaceuticals: A Mixture Of Opportunities
Regulatory Review
Intellectual Property Environment
Pricing Regime
Reimbursement Regime
Market Overview
Healthcare Sector
Table: Healthcare Resources (Serbia 2011-2016)
Table: Healthcare Personnel (Serbia 2011-2016)
Table: Healthcare Activity (Serbia 2011-2016)
Research & Development
Clinical Trials
Epidemiology
Competitive Landscape
Research-Based Industry
Table: Multinational Market Activity
Generic Drugmakers
Pharmaceutical Distribution
Pharmaceutical Retail Sector
Company Profile
Galenika
Hemofarm (Stada)
Demographic Forecast
Table: Population Headline Indicators (Serbia 2005-2025)
Table: Population By Age Group (Serbia 2005-2025)
Table: Population By Age Group % (Serbia 2005-2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Table: Indicators - Rationale And Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report